The development of the new cancer virus, cell therapy for ovarian cancer and the analysis of immune system response

2011 Fiscal Year Final Research Report

• Project/Area Number: 21592128
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Obstetrics and gynecology
• Research Institution: Ehime University (2011); Nagoya University (2009-2010)
• Principal Investigator: NAWA Akihiro 愛媛大学, 大学院・医学系研究科, 教授 (90242859)
• Co-Investigator(Kenkyū-buntansha): KIKKAWA Fumitaka 名古屋大学, 大学院医学系研究科, 教授 (40224985)
• Project Period (FY): 2009 – 2011
• Keywords: がん幹細胞 / CD133陽性細胞 / OATP8遺伝子 / タキソール / 薬剤耐性

Research Abstract

We have developed replication-competent, attenuated herpes simplex virus-1(HSV-1) mutants, which have been evaluated for their oncolytic activities. However, the host immune system remains a significant obstacle to effective intraperitoneal administration of these viruses in the clinical setting. In this study, we investigated the use of these HSV-1 mutants as oncolytic agents against ovarian cancer and human peritoneal mesothelial cells as carrier cells for intraperitoneal therapy. Our results indicate that these HSV-1 mutants exerts a potent oncolytic effect on ovarian cancer, which may be further enhanced by the utilization of a carrier cell delivery system, based on amplification of viral load and possibly on avoidance of neutralizing antibodies.